BridgeMD
Phase 1/2 study of Nivolumab and Relatlimab in Combination with Bevacizumab in First-line HCC
EU CTIS ID: 2024-510649-33-00
What this study is testing
1. To determine the RP2D (recommended Phase 2 dose) of relatlimab, nivolumab, and bevacizumab triplet combination in participants with advanced/metastatic HCC (hepatocellular carcinoma) who have not received prior systemic therapy. 2. To evaluate ORR (objective response rate) of the relatlimab, nivolumab, and bevacizumab triplet combination relative to nivolumab and bevacizumab doublet combination in all randomized participants with advanced/metastatic HCC who have not received prior systemic therapy.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 18 years of age
- Previously untreated for advanced/metastatic HCC
- ECOG 0-1
- Child-Pugh A
- Barcelona Clinical Liver Cancer stage B or C
- For detailed inclusion criteria, please refer to clinical protocol.
You likely can't join if
- Fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
- Prior disease history with increased risk of bleeding
- Clinically significant ascites
- Use of anticoagulant therapies
- For detailed exclusion criteria, please refer to clinical protocol.
The study team makes the final eligibility decision.
Where it's taking place
- Japan
- Singapore
- China
- Hong Kong
- Taiwan
- Korea, Republic of
- Australia
- United States
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Japan; Singapore; China; Hong Kong; Taiwan; Korea, Republic of and 3 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.